Ludwig Kappos from University of Basel: Siponimod Shows Promise for Secondary Progressive Multiple Sclerosis

September 20, 2016
Adam Hochron

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

Ludwig Kappos, MD, from the University of Basel discussed what could be a breakthrough treatment for siponimod at the annual ECTRIMS conference in London. Kappos said that while the medication is not a final step in the treatment of the condition, it is a solid first step to help patients that until now did not have a new treatment option on the horizon.